Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for virology, oncology and other therapeutic areas in the United States, Europe, and ...

In recent trading, shares of Gilead Sciences Inc (Symbol: GILD) have crossed above the average analyst 12-month target price of $111.77, changing hands for $112.26/share. When a stock reaches the ...

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

Gilead Sciences Inc (Symbol: GILD) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $22.93B worth of stock held by ETFs, and above-average ''DividendRank'' statistics ...

It has been about a month since the last earnings report for Gilead Sciences (GILD). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Gilead Sciences recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio ...

**NM signifies a non meaningful value. A dash signifies the data is not available.